Based on recent data, Cidara Therapeutics, Inc. (CDTX) shows an Average True Range (ATR) of 3.01 and an Enterprise Value of 23.86M. Its average trading volume over the past 3 months is 1.43M, indicating liquidity. These fundamental metrics provide insight into CDTX's underlying financial health and market activity.
Cidara Therapeutics, Inc. (CDTX) technical indicators as of December 22, 2025: the SMA 20 is 0.3%, SMA 50 at 36.4%, and SMA 200 at 199.35%. The RSI 14 value is 85.1, suggesting its current momentum. These technical analysis signals help assess CDTX's price trends and potential future movements.
Cidara Therapeutics, Inc. (CDTX) stock performance overview as of December 22, 2025: The 52-week high is $221.2 (currently -0.18% below), and the 52-week low is $15.22 (currently 1,350.72% above). Over the past year, CDTX's performance is 865.03%, compared to the S&P 500's 12.87% change.
According to market data, Cidara Therapeutics, Inc. (CDTX) stock's recent performance metrics show that over the last month, CDTX is 1.09%, with a Year-to-Date (YTD) performance of 721.43%. Over the past year, the stock has seen a 865.03% change. These figures summarize CDTX's price movements across various periods, reflecting its historical returns.
According to current financial data, CDTX stock's P/E (TTM) ratio is -32.13, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for CDTX, including P/S (N/A), P/B (14.05), and P/FCF (-42.12), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep